Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis
Executive Summary
After an initial rejection, Roche's IL-6 drug RoActemra has received support from the UK's health technology assessment body to treat giant cell arteritis in a subset of patients, provided the treatment with the drug is permitted for one year at the most.
You may also be interested in...
Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Canada Boosts Postmarket Device Safety With New Reporting Rules
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: